Arcturus Therapeutics Ltd (NASDAQ:ARCT) Director Peter C. Farrell Acquires 9,113 Shares
Arcturus Therapeutics Ltd (NASDAQ:ARCT) Director Peter C. Farrell acquired 9,113 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was bought at an average price of $10.94 per share, for a total transaction of $99,696.22. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of ARCT traded down $0.26 during mid-day trading on Wednesday, hitting $10.31. 66,102 shares of the company’s stock were exchanged, compared to its average volume of 61,703. The firm has a fifty day moving average of $10.45 and a two-hundred day moving average of $7.52. Arcturus Therapeutics Ltd has a twelve month low of $4.11 and a twelve month high of $15.50. The stock has a market cap of $147.12 million, a price-to-earnings ratio of -4.77 and a beta of 2.36. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 2.43.
Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, August 15th. The biotechnology company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.46. Arcturus Therapeutics had a negative net margin of 50.32% and a negative return on equity of 112.75%. The company had revenue of $10.15 million for the quarter, compared to analyst estimates of $4.01 million. On average, equities analysts predict that Arcturus Therapeutics Ltd will post -1.94 earnings per share for the current year.
ARCT has been the topic of several analyst reports. Chardan Capital set a $18.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. Zacks Investment Research lowered shares of Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright set a $18.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 16th. ValuEngine lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Finally, Brookline Capital Management restated a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $15.33.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Recommended Story: Ex-Dividend
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.